{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:48:56Z","timestamp":1778514536938,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1038\/s41417-019-0110-1","type":"journal-article","created":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T23:02:49Z","timestamp":1560726169000},"page":"383-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers"],"prefix":"10.1038","volume":"27","author":[{"given":"Paula","family":"Barlab\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana de","family":"Sostoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Alberto","family":"Fajardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Alemany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3105","authenticated-orcid":false,"given":"Rafael","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"110_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2016.06.009","volume":"21","author":"A Rosewell Shaw","year":"2016","unstructured":"Rosewell Shaw A, Suzuki M. Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol. 2016;21:9\u201315.","journal-title":"Curr Opin Virol"},{"key":"110_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/156652311796150363","volume":"11","author":"R Khare","year":"2011","unstructured":"Khare R, Chen CY, Weaver EA, Barry MA. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther. 2011;11:241\u201358.","journal-title":"Curr Gene Ther"},{"key":"110_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/gt.2015.41","volume":"22","author":"A Rodriguez-Garcia","year":"2015","unstructured":"Rodriguez-Garcia A, Svensson E, Gil-Hoyos R, Fajardo CA, Rojas LA, Arias-Badia M, et al. Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity. Gene Ther. 2015;22:596\u2013601.","journal-title":"Gene Ther"},{"key":"110_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12185-014-1537-7","volume":"99","author":"R Uchibori","year":"2014","unstructured":"Uchibori R, Tsukahara T, Ohmine K, Ozawa K. Cancer gene therapy using mesenchymal stem cells. Int J Hematol. 2014;99:377\u201382.","journal-title":"Int J Hematol"},{"key":"110_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/1535-7163.MCT-18-0431","volume":"18","author":"R Moreno","year":"2019","unstructured":"Moreno R, Fajardo CA, Farrera-Sal M, Perise-Barrios AJ, Morales-Molina A, Al-Zaher AA, et al. Enhanced antitumor efficacy of oncolytic adenovirus-loaded menstrual blood-derived mesenchymal stem cells in combination with peripheral blood mononuclear cells. Mol Cancer Ther. 2019;18:127\u201338.","journal-title":"Mol Cancer Ther"},{"key":"110_CR6","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","volume":"77","author":"CA Fajardo","year":"2017","unstructured":"Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, et al. Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res. 2017;77:2052\u201363.","journal-title":"Cancer Res"},{"key":"110_CR7","first-page":"22","volume":"11","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11:22\u201330.","journal-title":"Curr Opin Mol Ther"},{"key":"110_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","volume":"43","author":"S Offner","year":"2006","unstructured":"Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006;43:763\u201371.","journal-title":"Mol Immunol"},{"key":"110_CR9","doi-asserted-by":"publisher","first-page":"3615729","DOI":"10.1155\/2017\/3615729","volume":"2017","author":"R Moreno","year":"2017","unstructured":"Moreno R, Rojas LA, Villellas FV, Soriano VC, Garcia-Castro J, Fajardo CA, et al. Human menstrual blood-derived mesenchymal stem cells as potential cell carriers for oncolytic adenovirus. Stem cells Int. 2017;2017:3615729.","journal-title":"Stem cells Int"},{"key":"110_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2015.11.036","volume":"371","author":"GJ Melen","year":"2016","unstructured":"Melen GJ, Franco-Luzon L, Ruano D, Gonzalez-Murillo A, Alfranca A, Casco F, et al. Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Lett. 2016;371:161\u201370.","journal-title":"Cancer Lett"},{"key":"110_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omto.2017.06.002","volume":"6","author":"AL Alfano","year":"2017","unstructured":"Alfano AL, Nicola Candia A, Cuneo N, Guttlein LN, Soderini A, Rotondaro C, et al. Oncolytic adenovirus-loaded menstrual blood stem cells overcome the blockade of viral activity exerted by ovarian cancer ascites. Mol Ther Oncolytics. 2017;6:31\u201344.","journal-title":"Mol Ther Oncolytics"},{"key":"110_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2017.07.002","volume":"6","author":"A Szoor","year":"2017","unstructured":"Szoor A, Vaidya A, Velasquez MP, Mei Z, Galvan DL, Torres D, et al. T cell-activating mesenchymal stem cells as a biotherapeutic for HCC. Mol Ther Oncolytics. 2017;6:69\u201379.","journal-title":"Mol Ther Oncolytics"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-019-0110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-019-0110-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-019-0110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:23Z","timestamp":1684617023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-019-0110-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1038\/s41417-019-0110-1","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"13 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}